Volition Sponsors Upcoming GenomeWeb Webinar

Core Insights - VolitionRx Limited is sponsoring a GenomeWeb webinar focused on epigenetic modifications for biomarker and drug discovery, scheduled for October 8, 2025 [1][2]. Company Overview - VolitionRx is a multi-national epigenetics company dedicated to advancing the science of epigenetics, aiming to improve outcomes for patients with life-altering diseases through early detection and monitoring [7][8]. - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including certain cancers and conditions associated with NETosis, such as sepsis [8]. Webinar Details - The webinar will feature Dr. Eric Ariazi discussing major epigenetic pathways and their implications in health and disease, particularly focusing on cancer immunoediting and pharmacologic inhibitors [3]. - Dr. Marielle Herzog will present case studies on Volition's Nu.Q assays, which are designed to support disease research and clinical development [4]. Nu.Q® Discover Program - The Nu.Q® Discover program offers drug developers and scientists access to advanced assays for rapid epigenetic profiling, facilitating research from discovery to market readiness [5][6]. - This program utilizes proprietary nucleosome quantification technology, serving as a valuable tool for R&D professionals in pharmaco-epigenetics [6].